Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.39 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13734058 | 0.86 | FDPS (0.49) | OPRK1FDPSMAPK1MEN1KMT2A | |
| SCHEMBL19323053 | 0.83 | OPRK1 (0.47) | OPRK1FDPSMAPK1MEN1KMT2A | |
| SCHEMBL19323069 | 0.83 | OPRK1 (0.44) | OPRK1FDPSMAPK1MEN1KMT2A | |
| SCHEMBL2092795 | 0.83 | NAMPT (0.47) | FDPSMEN1KMT2AMTNR1AL3MBTL1 | |
| SCHEMBL4150247 | 0.81 | OPRK1 (0.43) | OPRK1FDPSMAPK1MEN1KMT2A | |
| SCHEMBL16133684 | 0.81 | MAPT (0.49) | OPRK1FDPSMAPK1MEN1KMT2A | |
| SCHEMBL24015863 | 0.80 | FNTA (0.43) | FDPSMAPK1SMN1; SMN2MTNR1AL3MBTL1 | |
| SCHEMBL16136347 | 0.79 | FPR2 (0.49) | KMT2ANPSR1SMN1; SMN2FPR2MTNR1A | |
| SCHEMBL14621848 | 0.79 | FDPS (0.43) | OPRK1FDPSMAPK1MEN1KMT2A | |
| SCHEMBL21765308 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023072974-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2021224291-A1 | TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS | MERCK PATENT GMBH (DE) | 2021-11-11 | — | — | WO | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-9776996-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20160326170-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2016-11-10 | — | — | US | disclosed |
| US-9365570-B2 | Substituted 6, 5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2016-01-28 | — | — | US | disclosed |
| US-20150246916-A1 | Substituted 6, 5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2015-09-03 | — | — | US | disclosed |
| US-9108953-B2 | Quinoline derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| WO-2015080707-A1 | QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| US-9045477-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150148344-A1 | QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2015-05-28 | — | — | US | disclosed |
| US-20140296283-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | PFIZER INC | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | DGAT1, DGAT2, MOGAT2 | OPRK1 1343/4885FDPS 441/4885MAPK1 3672/4885 |
| US-20150148344-A1 | QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD7, BRD3 | OPRK1 1847/4885FDPS 4175/4885MAPK1 1379/4885 |
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | OPRK1 3128/4885FDPS 49/4885MAPK1 4815/4885 |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | OPRK1 1920/4885FDPS 226/4885MAPK1 2374/4885 |
| US-20150246916-A1 | Substituted 6, 5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | OPRK1 3128/4885FDPS 49/4885MAPK1 4815/4885 |
| US-20140296283-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | OPRK1 3128/4885FDPS 49/4885MAPK1 4815/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | OPRK1 3944/4885FDPS 805/4885MAPK1 1369/4885 |
| US-20160326170-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, PAICS, CYP4B1 | OPRK1 3128/4885FDPS 49/4885MAPK1 4815/4885 |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | EIF2AK4, GCN1, GNAI2 | OPRK1 4076/4885FDPS 1149/4885MAPK1 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.